Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/aje/kwaa189 http://scihub22266oqcxt.onion/10.1093/aje/kwaa189 32860038!7499476!32860038     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 243.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 243.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 243.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Am+J+Epidemiol 2021 ; 190 (4): 491-495 Nephropedia Template TP {{tp|p=32860038|t=2021. Concerns About the Special Article on Hydroxychloroquine and Azithromycin in High-Risk Outpatients With COVID-19 |pdf=|usr=}}{{32860038}} gab.com Text Concerns About the Special Article on Hydroxychloroquine and Azithromycin in High-Risk Outpatients With COVID-19 JO: Am J Epidemiol http://www.kidney.de/pget.php?&tw=1&pmid=32860038 #FOAvip In May 2020, the Journal published an opinion piece by a member of the Editorial Board, in which the author reviewed several papers and argued that using hydroxychloroquine (HCQ) + azithromycin (AZ) early to treat symptomatic coronavirus disease 2019 (COVID-19) cases in high-risk patients should be broadly applied. As members of the Journal's Editorial Board, we are strongly supportive of open debate in science, which is essential even on highly contentious issues. However, we must also be thorough in our examination of the facts and open to changing our minds when new information arises. In this commentary, we document several important errors in the manuscript, review the literature presented, and demonstrate why it is not of sufficient quality to support scale up of HCQ + AZ, and then discuss the literature that has been generated since the publication, which also does not support use of this therapy. Unfortunately, the current scientific evidence does not support HCQ + AZ as an effective treatment for COVID-19, if it ever did, and even suggests many risks. Continuing to push the view that it is an essential treatment in the face of this evidence is irresponsible and harmful to the many people already suffering from infection. Twit Text FOAVip Concerns About the Special Article on Hydroxychloroquine and Azithromycin in High-Risk Outpatients With COVID-19 ????Am J Epidemiol http://www.kidney.de/pget.php?&tw=1&pmid=32860038 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32860038 #FOAvip English Wikipedia <ref>{{Cite pmid|32860038}}</ref> Concerns About the Special Article on Hydroxychloroquine and Azithromycin in High-Risk Outpatients With COVID-19 #MMPMID32860038 Fox MP; D'Agostino McGowan L; James BD; Lessler J; Mehta SH; Murray EJ Am J Epidemiol 2021[Apr]; 190 (4): 491-495 PMID32860038show ga In May 2020, the Journal published an opinion piece by a member of the Editorial Board, in which the author reviewed several papers and argued that using hydroxychloroquine (HCQ) + azithromycin (AZ) early to treat symptomatic coronavirus disease 2019 (COVID-19) cases in high-risk patients should be broadly applied. As members of the Journal's Editorial Board, we are strongly supportive of open debate in science, which is essential even on highly contentious issues. However, we must also be thorough in our examination of the facts and open to changing our minds when new information arises. In this commentary, we document several important errors in the manuscript, review the literature presented, and demonstrate why it is not of sufficient quality to support scale up of HCQ + AZ, and then discuss the literature that has been generated since the publication, which also does not support use of this therapy. Unfortunately, the current scientific evidence does not support HCQ + AZ as an effective treatment for COVID-19, if it ever did, and even suggests many risks. Continuing to push the view that it is an essential treatment in the face of this evidence is irresponsible and harmful to the many people already suffering from infection. |*COVID-19 Drug Treatment[MESH] |*Hydroxychloroquine[MESH] |Azithromycin[MESH] |Humans[MESH] |Outpatients[MESH] |Pandemics[MESH] |SARS-CoV-2[MESH]Concerns About the Special Article on Hydroxychloroquine and Azithromy(epmc).pdf DeepDyve Pubget Overpricing